secwatch.observer — SEC 8-K summary
======================================

Issuer:     LISATA THERAPEUTICS, INC. (LSTA)
CIK:        0000320017
Form:       8-K
Filed at:   2025-07-15T23:59:59+00:00
Accession:  0000320017-25-000048
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lisata Therapeutics granted US composition-of-matter patent for certepetide expiring 2040
--------------------------------------------------------------------------------

- U.S. Patent No. 12,351,653 covers certepetide's chemical structure and pharmacokinetic properties.
- Patent expires March 2040 with opportunity for patent term extension.
- CEO states strengthened IP estate and long-term market exclusivity for certepetide.
- Patent includes claims for treating solid tumor cancers and methods of manufacture.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/320017/000032001725000048/0000320017-25-000048-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/320017/000032001725000048/clbs-20250715.htm
  HTML page:      https://secwatch.observer/filing/0000320017-25-000048

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer